Literature DB >> 27190822

Leukaemic Transformation of Multiple Myeloma in Post Chemotherapy Remission Phase.

Palak Agarwal1, Prachi Nayak2, Premala Anthony Singh2, Bal Krishna Mishra3.   

Abstract

Plasma cell leukaemia is diagnosed when plasma cells are >20% in the peripheral blood. Plasma cell leukaemia may be present at the time of diagnosis (primary plasma cell leukaemia) or may evolve from multiple myeloma (secondary plasma cell leukaemia). We report case of a 62-year-old male who was diagnosed with multiple myeloma. He was treated with combination of prednisolone, melphalan and thalidomide. After 6 years he had Worsening of symptoms and also developed a scalp swelling. The swelling was diagnosed as plasmacytoma on fine needle aspiration cytology and confirmed on histopathology. Complete haemogram showed-Haemoglobin - 8g/dl, Total Leucocyte Count - 4300/μl, Differential leucocyte count - Neutrophil-40%, Lymphocyte-28%, Eosinophil-01%, Monocyte-10%, Atypical cells-21%, Platelet count- 1.5 lacs/μl. Peripheral blood showed rouleaux formation and plasma cells. Serum protein electrophoresis revealed an M spike (3.26 g/dl). So, patient was diagnosed as secondary plasma cell leukaemia. Weekly bortezomib and dexamethasone combination chemotherapy was given to the patient. Patient is on monthly follow up. Here we present a detailed case history of this patient.

Entities:  

Keywords:  Bone Marrow; Bortezomib; Hemogram; SPEP

Year:  2016        PMID: 27190822      PMCID: PMC4866120          DOI: 10.7860/JCDR/2016/17370.7696

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  7 in total

1.  Plasma cell leukemia.

Authors:  Moria A Gertz; Francis K Buadi
Journal:  Haematologica       Date:  2010-05       Impact factor: 9.941

2.  Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.

Authors:  Eirini Katodritou; Evangelos Terpos; Charikleia Kelaidi; Maria Kotsopoulou; Sossana Delimpasi; Marie-Christine Kyrtsonis; Argiris Symeonidis; Nikos Giannakoulas; Aikaterini Stefanoudaki; Dimitrios Christoulas; Christina Chatziaggelidou; Vassiliki Gastari; Nikos Spyridis; Evgenia Verrou; Pavlina Konstantinidou; Kostas Zervas; Meletios A Dimopoulos
Journal:  Am J Hematol       Date:  2013-11-21       Impact factor: 10.047

3.  Plasma cell leukemia following treatment with radiotherapy and melphalan.

Authors:  N A Buskard; D A Boyes; L Grossman
Journal:  Can Med Assoc J       Date:  1977-10-08       Impact factor: 8.262

4.  Acute leukemia after alkylating-agent therapy of ovarian cancer.

Authors:  R R Reimer; R Hoover; J F Fraumeni; R C Young
Journal:  N Engl J Med       Date:  1977-07-28       Impact factor: 91.245

5.  The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.

Authors:  C Pellat-Deceunynck; S Barillé; G Jego; D Puthier; N Robillard; D Pineau; M J Rapp; J L Harousseau; M Amiot; R Bataille
Journal:  Leukemia       Date:  1998-12       Impact factor: 11.528

6.  Secondary plasma cell leukemia.

Authors:  Ionela Rotaru; G Găman; Daniela Dumitrescu; Camelia Foarfă
Journal:  Rom J Morphol Embryol       Date:  2012       Impact factor: 1.033

Review 7.  Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.

Authors:  Vittorio Simeon; Katia Todoerti; Francesco La Rocca; Antonella Caivano; Stefania Trino; Marta Lionetti; Luca Agnelli; Luciana De Luca; Ilaria Laurenzana; Antonino Neri; Pellegrino Musto
Journal:  Int J Mol Sci       Date:  2015-07-30       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.